Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WU CART 007

Next Previous
Drug Profile

WU CART 007

Alternative Names: Allogenic CAR-T cell therapies - Wugen; Anti-CD7 Allogeneic CAR T Cells - Wugen; WU-CART-007

Latest Information Update: 21 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator WUGEN
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor T-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Precursor T-cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Haematological malignancies

Most Recent Events

  • 31 Jan 2025 Phase-II clinical trials in Precursor T-cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater, In infants, In children, In adolescents, In adults, In the elderly) in USA (IV) (NCT06514794)
  • 07 Dec 2024 Efficacy and adverse events data from a phase I trial in Haematological malignancies presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 12 Nov 2024 Wugen plans a phase II trial for Precursor-T-cell lymphoblastic leukaemia lymphoma (Second-line therapy or greater, In infants, In children, In adults, In adolescents, In the elderly) in USA, Europe, Asia and Australia in the first quarter of 2025 (IV, infusion) (NCT06514794)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top